Dr. Conconi at ESMO 2024: Charting the Course for Hematologic Malignancies Treatment

Dr. Conconi at ESMO 2024: Charting the Course for Hematologic Malignancies Treatment

The 2024 Annual Meeting of the European Society for Medical Oncology (ESMO) was recently held in Barcelona, Spain. As one of the top international conferences in the field of oncology, it gathered experts and scholars from around the world to share the latest research findings and explore future development directions. During this conference, several landmark studies in the field of hematologic malignancies were presented, providing valuable insights and references for current clinical practice and future research. Hematology Frontier invited Dr. Annarita Conconi from the University of Eastern Piedmont in Italy, one of the Chairs of the Mini Oral Session on Hematologic Malignancies, to comment on these landmark studies and to look ahead at the future trends in hematologic oncology.
Groundbreaking Honors at ILCA 2024: Celebrating Liver Cancer Research Milestones

Groundbreaking Honors at ILCA 2024: Celebrating Liver Cancer Research Milestones

The 2024 International Liver Cancer Association (ILCA) Conference recently held its highly anticipated awards ceremony in Rio de Janeiro, Brazil. This event attracted attention from liver cancer researchers worldwide, recognizing those who made significant contributions to the field over the past year. The ceremony aimed to further promote global collaboration and innovation in liver cancer research.
Advancing the Field: Dr. Pei Dong Discusses Groundbreaking Neoadjuvant Therapies for Renal Cancer at CSCO 2024

Advancing the Field: Dr. Pei Dong Discusses Groundbreaking Neoadjuvant Therapies for Renal Cancer at CSCO 2024

Surgery is a fundamental treatment for renal cancer, particularly for patients with stage I and II cancers, where surgery can cure the majority of cases and ensure long-term survival. At the 2024 CSCO Annual Meeting, Urology Frontier invited Dr. Pei Dong from Sun Yat-sen University Cancer Center to discuss this year’s key updates in the CSCO guidelines for surgical treatment of renal cancer, comparisons between single-port and traditional laparoscopic nephrectomy, and the role of neoadjuvant therapy in enhancing surgical outcomes.
Decoding Gene Silence: Nobel Honors Pioneers of microRNA in Blood Cancer Therapies

Decoding Gene Silence: Nobel Honors Pioneers of microRNA in Blood Cancer Therapies

The 2024 Nobel Prize in Physiology or Medicine has once again brought the spotlight onto the field of gene regulation. This year, American scientists Victor Ambros and Gary Ruvkun were honored with the prestigious award for their pioneering research on microRNA and its role in post-transcriptional gene regulation. Their groundbreaking discoveries not only opened new horizons in understanding gene regulation but also offered new perspectives and methods for studying and treating hematological diseases such as leukemia.
3D Surgery Breakthrough: Dr. Renquan Zhang Talks Innovative Treatment for Elderly Esophageal Cancer Patients

3D Surgery Breakthrough: Dr. Renquan Zhang Talks Innovative Treatment for Elderly Esophageal Cancer Patients

From September 26 to 28, 2024, the China Anti-Cancer Association (CACA) and the CACA Integrative Esophageal Cancer Committee hosted the 2024 CACA Integrative Esophageal Cancer Academic Conference in Hefei. This prestigious event gathered leading experts in the field of esophageal cancer from China and abroad. The topics ranged from cancer prevention, early diagnosis and treatment, standardized therapy, and integrated treatment approaches. Oncology Frontier had the opportunity to interview Dr. Renquan Zhang from The First Affiliated Hospital of Anhui Medical University (AMU) to discuss advancements in the diagnosis and treatment of esophageal cancer. Below is a summary of the interview for our readers.
Breaking News: ISDE 2024 Spotlights Groundbreaking Predictive Vital Sign Tech for Esophageal Cancer Surgery

Breaking News: ISDE 2024 Spotlights Groundbreaking Predictive Vital Sign Tech for Esophageal Cancer Surgery

From September 22nd to 24th, 2024, the 20th International Society for Diseases of the Esophagus (ISDE) conference was grandly held in Edinburgh, Scotland. A study by Dr. Andrew Seely from the University of Ottawa's Faculty of Medicine on predictive vital sign monitoring during the perioperative period for esophageal cancer was selected for abstract presentation at the conference (Abstract No.: S19.05). Oncology Frontier conducted an exclusive interview with Prof. Seely at the conference venue to discuss his research.
Filipa Fonseca Challenges Traditional EGJ Cancer Classification with Innovative Approach at ISDE 2024

Filipa Fonseca Challenges Traditional EGJ Cancer Classification with Innovative Approach at ISDE 2024

From September 22nd to 24th, 2024, the 20th International Society for Diseases of the Esophagus (ISDE) conference was grandly held in Edinburgh, Scotland. Dr. Filipa Fonseca from the Lisbon Oncology Research Center presented a study on the modified Siewert classification for adenocarcinoma of the esophagogastric junction (EGJ) at the Late-Breaking Oral Abstract session (Abstract No.: LB-OA02.07), which sparked extensive discussion and interest. Oncology Frontier conducted an exclusive interview with Prof. Fonseca at the conference venue regarding this classification method.
ISDE 2024 | Groundbreaking: Prehabilitation Transforms Borderline Resectable Esophageal Cancer Patients into Surgical Candidates

ISDE 2024 | Groundbreaking: Prehabilitation Transforms Borderline Resectable Esophageal Cancer Patients into Surgical Candidates

The 20th International Society for Diseases of the Esophagus (ISDE) conference took place in Edinburgh, Scotland, from September 22nd to 24th, 2024. At the conference, a study by Dr. Krishna Moorthy from the Royal College of Surgeons in the UK on whether prehabilitation can increase the surgical opportunities for esophageal cancer patients was selected for presentation (Abstract No.: S19.02). Oncology Frontier conducted an exclusive interview with Professor Moorthy at the conference venue about this research. The interview content has been organized and the relevant study abstract is attached for reference.
Integrative Medicine Shines at CACA: Dr. Liu Hong Outlines New Horizons in Esophageal Cancer Treatment

Integrative Medicine Shines at CACA: Dr. Liu Hong Outlines New Horizons in Esophageal Cancer Treatment

From September 26 to 28, 2024, the China Anti-Cancer Association (CACA) and the CACA Integrative Esophageal Cancer Committee hosted the 2024 CACA Integrative Esophageal Cancer Academic Conference in Hefei. The conference, under the theme “Winning in Integration for Cancer Prevention and Treatment,” gathered the latest research developments and clinical experiences from experts in esophageal cancer worldwide. During the event, Oncology Frontier had the opportunity to interview Dr. Liu Hong from The First Affiliated Hospital of Air Force Medical University (Xijing Hospital). In this interview, Professor Hong delves into the trends of integrative treatment, individualized care, and the importance of comprehensive patient management. Below is the full transcript of the interview for our readers.